Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.
